Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cell and gene therapy manufacturing

- PMLiVE

New efficacy data boosts Aimovig’s migraine market lead

Data should help boost uptake

- PMLiVE

Syncona start-up Quell Therapeutics appoints chief exec

Biotech focusing on Tregs

- PMLiVE

Sanofi exiting Voyager gene therapy pact is ‘surprising’, says analyst

Move cuts pipeline depth, says GlobalData

Novartis day

Novartis close to US bribery settlement

Company faces huge damages pay out

- PMLiVE

Rival Novartis, Merck drugs square up on rare lung cancer at ASCO

An inflection point for MET-inhibitor class

- PMLiVE

Oxford Biomedica gets £53m cash injection from Novo venture arm

Cell and gene therapy specialist needs to invest to stay ahead

- PMLiVE

Novartis secures US approval – and payers’ blessing – for $2m gene therapy Zolgensma

Novel financing deal could be sector's future

Novartis day

FDA clears Novartis’ new breast cancer drug Piqray

Blockbuster potential for PI3K drug

- PMLiVE

Novartis sees five new $1bn-plus launches in next two years

CEO defends likely high price of Zolgensma

- PMLiVE

Verily unveils next-gen trials alliance with Novartis, Pfizer

New data methods and tech will be used to streamline trials

- PMLiVE

Health comms agency emotive hires new cell and gene therapy leader

New division will cater to fast-expanding field

- PMLiVE

Europe responding to gene therapy challenge, but picture remains fragmented

Germany, Italy and England using outcomes-based deals

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links